Ian M. Rosenthal, Ph.D.
Affiliations: | 2007 | Johns Hopkins University, Baltimore, MD |
Area:
Public Health, Microbiology BiologyGoogle:
"Ian Rosenthal"Cross-listing: PHTree
Parents
Sign in to add mentor| Jacques Grosset | grad student | 2007 | Johns Hopkins | |
| (Improving the treatment of experimental tuberculosis with combined rifapentine- and moxifloxacin-containing drug regimens.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nuermberger EL, Rosenthal IM, Tasneen R, et al. (2013) Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrobial Agents and Chemotherapy. 57: 1104-5 |
| Rosenthal IM, Tasneen R, Peloquin CA, et al. (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrobial Agents and Chemotherapy. 56: 4331-40 |
| Zhang M, Li SY, Rosenthal IM, et al. (2011) Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. American Journal of Respiratory and Critical Care Medicine. 183: 1254-61 |
| Zhang T, Zhang M, Rosenthal IM, et al. (2009) Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine. 180: 1151-7 |
| Almeida D, Nuermberger E, Tasneen R, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 53: 4178-84 |
| Rosenthal IM, Zhang M, Almeida D, et al. (2008) Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American Journal of Respiratory and Critical Care Medicine. 178: 989-93 |
| Nuermberger E, Tyagi S, Tasneen R, et al. (2008) Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 52: 1522-4 |
| Rosenthal IM, Zhang M, Williams KN, et al. (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. Plos Medicine. 4: e344 |
| Nuermberger E, Rosenthal I, Tyagi S, et al. (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 50: 2621-5 |
| Rosenthal IM, Williams K, Tyagi S, et al. (2006) Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 174: 94-101 |